A Phase 3 interventional study of Normal saline as placebo comparator and Intravenous ibuprofen in Pain, sponsored by Cumberland Pharmaceuticals. Completed at 13 sites in 2 countries. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-06-22.
Sponsored by Cumberland Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 86 studies testing ibuprofen in Pain — 6 open to participants now, 6 under way, none of them phase 3. Ibuprofen · Pain.
Among the 86 studies testing ibuprofen in Pain, this one is the 11th largest by enrollment, is the only one that started in 2005, is one of 22 in phase 3, and was the 1st registered.
10,075 studies on the registry are indexed under Pain; 1,649 are open to participants now.
Browse Pain studies →6 of the 86 studies testing ibuprofen in Pain are open now, in 4 countries. Recruiting first, the newest first:
Armed Forces Post Graduate Medical Institute (AFPGMI), Rawalpindi · Sites in Pakistan
Ages 18–60
October University for Modern Sciences and Arts · Sites in Egypt
Ages 6–12
Armed Forces Institute of Dentistry, Pakistan · Sites in Pakistan
Ages 18–50 · Healthy volunteers
Ankara City Hospital Bilkent · Sites in Turkey
Ages 18–80
Benaroya Research Institute · Sites in United States
Ages 18+ · Men only · Healthy volunteers
By country, each count listing its studies:
Ibuprofen: first FDA approval 1974 (MOTRIN), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 929 Pain studies recruiting now, 384 (41%) set no upper age limit and 433 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.
This study: 18 Years to 70 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
86 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 10 · Phase 3 22 · Phase 4 30
First in 1998; this study’s year is marked. 1 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 319 is above the median of 66 across 8,511 interventional studies indexed under Pain.
Median enrollment 100 across the 86 interventional studies. Of the 69 that completed or were terminated, 32 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 86 have an industry lead sponsor. The 10 most frequent:
Cumberland Pharmaceuticals is the lead sponsor of 49 studies on the registry; 1 is open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
Cumberland Pharmaceuticals has 6 studies filed under Pain — fewer than ten, so there is no comparison to draw.
2 of the studies testing ibuprofen in Pain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07512297University of GaziantepPain Control During ESWL Using Non-Opioid Analgesics | 2027-01-01 |
| NCT07275710Armed Forces Post Graduate Medical Institute (AFPGMI), RawalpindiRole of Alprazolam in Management of Post Endodontic Pain After Single Visit Root Canal Treatment. To Compare Mean Pain Score Between Two Group of Participants Undergoing Post Operative Pain Management After Single Visit Root Canal Treatment: NSAIDs Alone and a Combination of NSAIDs and Alprazolam. | 2027-01-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 86 studies testing ibuprofen in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study of Caldolor (IV ibuprofen) administered to post-operative hospitalized adult patients every 6 hours for 48 hours is to determine the efficacy of Caldolor compared to placebo for the treatment of post-operative pain as measured by reduction in the requirement for the narcotic analgesic, morphine, post surgery
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Intravenous ibuprofen
Other: Normal saline as placebo comparator
250 ml normal saline as a placebo comparator was administered every 6 hours for a total of eight doses over the first 48 hours. Those patients who received the initial eight doses could continue to receive additional doses as needed through the end of the treatment period (day 5)
Also known as: NS
800 mg intravenous ibuprofen diluted in 250 milliliters of normal saline was administered every 6 hours for a total of eight doses over the first 48 hours. Those patients who received the initial eight doses could continue to receive additional doses as needed through the end of the treatment period (day 5)
Also known as: Caldolor
Change in the Patient Demand for the Narcotic Analgesic, Morphine, Post Surgery
Change in the amount of morphine use (in milligrams) by subjects in each treatment group for a 24 hour period post-surgery
Time frame: 24 Hours
Participants were recruited from the medical practices and/or clinics of the investigator/sub-investigators.
| Milestone | Placebo | 800 mg Intravenous Ibuprofen |
|---|---|---|
| Started | 153 | 166 |
| Completed | 153 | 166 |
| Not completed | 0 | 0 |
Change in the amount of morphine use (in milligrams) by subjects in each treatment group for a 24 hour period post-surgery
| milligrams | Placebo | 800 mg Intravenous Ibuprofen |
|---|---|---|
| Change in the Patient Demand for the Narcotic Analgesic, Morphine, Post Surgery | 57.0 ± 2.4 | 48.7 ± 2.3 |
Collected over 14 Days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 6/153 (3.9%) | 149/153 (97.4%) |
| 800 mg Intravenous Ibuprofen | — | 12/166 (7.2%) | 150/166 (90.4%) |
| Event | Placebo | 800 mg Intravenous Ibuprofen |
|---|---|---|
| IleusGastrointestinal disorders | 1/153 | 3/166 |
| AtelectasisRespiratory, thoracic and mediastinal disorders | 2/153 | 0/166 |
| Oxygen saturation decreasedInvestigations | 1/153 | 0/166 |
| Peritoneal HemorrhageGastrointestinal disorders | 1/153 | 0/166 |
| CholecystitisHepatobiliary disorders | 1/153 | 0/166 |
| Abdominal AbscessInfections and infestations | 0/153 | 1/166 |
| Peritoneal abscessInfections and infestations | 0/153 | 1/166 |
| Wound drainageSurgical and medical procedures | 0/153 | 1/166 |
| TachycardiaCardiac disorders | 0/153 | 1/166 |
| Wound DihisenceInjury, poisoning and procedural complications | 0/153 | 1/166 |
| Event | Placebo | 800 mg Intravenous Ibuprofen |
|---|---|---|
| NauseaGastrointestinal disorders | 85/153 | 79/166 |
| FlatulenceGastrointestinal disorders | 34/153 | 42/166 |
| PruritisSkin and subcutaneous tissue disorders | 33/153 | 32/166 |
| ConstipationGastrointestinal disorders | 21/153 | 13/166 |
| VomitingGastrointestinal disorders | 12/153 | 15/166 |
| HeadacheNervous system disorders | 11/153 | 10/166 |
| PyrexiaGeneral disorders | 9/153 | 6/166 |
| Body temperature increasedInvestigations | 7/153 | 7/166 |
| Age, Customized(participants) | Placebo | 800 mg Intravenous Ibuprofen | Total |
|---|---|---|---|
| Less than or equal to 45 years | 104 | 110 | 214 |
| 45 to 70 years of age | 49 | 56 | 105 |
| Sex: Female, Male(Participants) | Placebo | 800 mg Intravenous Ibuprofen | Total |
|---|---|---|---|
| Female | 153 | 166 | 319 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | 800 mg Intravenous Ibuprofen | Total |
|---|---|---|---|
| Caucasian | 52 | 71 | 123 |
| Black or African American | 91 | 84 | 175 |
| Hispanic | 8 | 11 | 19 |
| Asian | 0 | 0 | 0 |
| Other | 2 | 0 | 2 |
| Region of Enrollment(participants) | Placebo | 800 mg Intravenous Ibuprofen | Total |
|---|---|---|---|
| United States | 153 | 166 | 319 |
| Weight(Kilograms) | Placebo | 800 mg Intravenous Ibuprofen | Total |
|---|---|---|---|
| Less than or equal to 75 kilograms | 57 | 61 | 118 |
| Greater than 75 kilograms | 96 | 105 | 201 |
The record gives a start of Jan 2005, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2011, 3 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ibuprofen